 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| ABX01 / Centauri Therap
One advantage of ABX-01's dual MOA is that it requires less dose. #IDWeek2022 (Twitter) - Oct 20, 2022
- ||| ABX01 / Centauri Therap
ABX-01 has a broad spectrum, including anti-pseudomonal activity #IDWeek2022 (Twitter) - Oct 20, 2022
- ||| ABX01 / Centauri Therap
ABX-01 has dual MOA: immunotherapeutic (recruits anti-Gal antibodies) and intrinsic antibacterial activity. #IDWeek2022 (Twitter) - Oct 20, 2022
- ABX01 / Centauri Therap
ABX-01, a novel immunotherapy to treat Gram-negative infections (145 AB) - Jul 23, 2022 - Abstract #IDWeek2022IDWEEK_96;